过去一年,中国创新药企凭借密集的License-out(对外授权)交易引爆资本市场。投资人一度热衷于License-out带来的短期估值跃升与确定性回报,将其视为创新药企成功的标准。但单纯依据license-out进行创新药投资也在当下遇到了新问题。资料来源:华源证券从数据来看,2025年License-out交易总额和数量相比2024年出现进一步的加速,信达生物与武田制药114亿美元的交易更是又...
Source Link过去一年,中国创新药企凭借密集的License-out(对外授权)交易引爆资本市场。投资人一度热衷于License-out带来的短期估值跃升与确定性回报,将其视为创新药企成功的标准。但单纯依据license-out进行创新药投资也在当下遇到了新问题。资料来源:华源证券从数据来看,2025年License-out交易总额和数量相比2024年出现进一步的加速,信达生物与武田制药114亿美元的交易更是又...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.